Nitric oxide synthase and cyclooxygenases: Distribution, regulation, and intervention in arthritis

Current Opinion in Rheumatology

Volumn 11, Issue 3, 1999, Pages 202-209

  Amin, Ashok R ^a,b   Attur, Mukundan ^a   Abramson, Steven B ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1BETA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

CARTILAGE; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0032998811     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199905000-00009     Document Type: Review

References (58)

1. 1 Nathan C: Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997, 100:2417-2423. This is a comprehensive review on the role of NO in various diseases.
2. 2 Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120. This review describes the structure, function and role of COX-1 and COX-2 in inflammatory diseases.
3. 2 in various diseases.
4. 4 Lloyd-Jones DM, Bloch KD: The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med 1996, 47:365-375.
5. 5 McIntyre M, Dominiczak AF: Nitric oxide and cardiovascular disease. Postgrad Med J 1997, 73:630-634.
6. 6 Koglin J, Glysing-Jensen T, Mudgett JS, Russell ME: Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation 1998, 97:2059-2065.
7. 7 Davies P, MacIntyre DE: Prostaglandins and inflammation. In Inflammation: Basic Principles and Clinical Correlates. Edited by Gallin JI, Goldstein IM, Snyderman R. New York: Raven Press; 1992:123-137.
8. 8 Wu KK: Inducible cyctooxygenase and nitric oxide synthase. Adv Pharmacol 1995, 33:179-201.
9. 2-deficient mice and in anti-interleukin-1-treated wild-type mice with unabated joint inflammation. Arthritis Rheum 1998, 41:634-646. This article shows the role of NO and IL-1β in in vivo models of inflammatory arthritis.
10. 10 Gilroy DW, Tomlinson A, Willoughby DA: Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflamm Res 1998, 47:79-85.
11. 11 Kirtikara K, Morham SG, Raghow R, Laulederkind SJ, Kanekura T, Goorha S, Ballou LR: Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. J Exp Med 1998, 187:517-523.
12. 12 Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996, 97:2672-2679.
13. 13 Salvemini D, Masferrer JL: Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo, and in vivo studies. Methods Enzymol 1996, 269:15-25.
14. 14 Amin AR, Abramson SB: The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1998, 10:263-268. This review discusses the role of NO in cartilage homeostasis and how it may affect chondrocyte functions.
15. 15 De MS, Novaes GS, Laurindo IM, Muscara MN, Maciel FM, Cossermelli W: Nitric oxide synthase inhibitor influences prostaglandin and interleukin-1 production in experimental arthritic joints. Inflamm Res 1997, 46:72-77.
16. 16 Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, et al: Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998, 41:1275-1286. This study demonstrates the role NO, IL-1β, and matrix metalloproteases in animal models of osteoarthritis. This study also suggests the multifunctional role of NO in arthritis.
17. 2 gene. J Immunol 1998, 160:2940-2946.
18. 18 Ding M, Zhang M, Wong JL, Rogers NE, Ignarro LJ, Voskuhl RR: Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice. J Immunol 1998, 160:2560-2564.
19. 19 Weinberg JB: Nitric oxide as an inflammatory mediator in autoimmune MRL-lpr/lpr mice. Environ Health Perspect 1998, 106(suppl 5):1131-1137.
20. 20 Amin AR, Attur MG, Abramson SB: Regulation of nitric oxide and inflammatory mediators in human osteoarthritis-affected cartilage: implication for pharmacological intervention. In The Pathophysiology and Clinical Applications of Nitric Oxide. Edited by Rubanyi GM. Singapore: Harwood Academic Publishers; 1999, in press. This is a comprehensive review on the role of inflammatory mediators in osteoarthritis.
21. 21 Gilroy DW, Tomlinson A, Greenslade K, Seed MP, Willoughby DA: The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat. Inflammation 1998, 22:509-519. This paper describes the role of specific and nonspecific COX-2 inhibitors on cartilage and bone metabolism in vivo.
22. 22 Portanova JP, Zhang Y, Anderson GD, Hauser SD, Masferrer JL, Seibert K, et al: Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996, 184:883-891.
23. 23 Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, et al: Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995, 96:2357-2363.
24. 24 Bellometti S, Galzigna L: Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. J Invest Med 1998, 46:140-145.
25. 25 Sawazaki Y: [Leukotriene B4, leukotriene C4 and prostaglandin E2 in the serum, synovial fluid and synovium in patients with rheumatoid arthritis]. Nippon Ika Daigaku Zasshi 1989, 56:559-564.
26. 26 Ueki Y, Miyake S, Tominaga Y, Eguchi K: Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 1996, 23:230-236.
27. 27 Grabowski PS, Wright PK, Van Helfrich MH, Ohshima H, Ralston SH: Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1997, 36:651-655.
28. 28 St CE, Wilkinson WE, Lang T, Sanders L, Misukonis MA, Gilkeson GS, et al: Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. J Exp Med 1996, 184:1173-1178.
29. 29 Melchiorri C, Meliconi R, Frizziero L, Silvestri T, Pulsatelli L, Mazzetti I, et al: Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998, 41:2165-2174. Evidence suggests that most of the inflammatory mediators in rheumatoid arthritis are upregulated in the synovial tissue, whereas in osteoarthritis, the inflammation is in the cartilage and less pronounced in the synovial tissue.
30. 30 Amin AR, Di Cesare P, Vyas P, Attur MG, Tzeng E, Billiar TR, et al: The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for up-regulated neuronal nitric oxide synthase. J Exp Med 1995, 182:2097-2102.
31. 31 Peunova N, Enikolopov G: Nitric oxide triggers a switch to growth arrest during differentiation of neuronal cells. Nature 1995, 375:68-73.
32. 32 Hayashi T, Abe E, Yamate T, Taguchi Y, Jasin HE: Nitric oxide production by superficial and deep articular chondrocytes. Arthritis Rheum 1997, 40:261-269.
33. 33 Knott I, Dieu M, Burton M, Lecomte V, Remacle J, Raes M: Differential effects of interleukin-1 alpha and beta on the arachidonic acid cascade in human synovial cells and chondrocytes in culture. Agents Actions 1993, 39:126-131.
34. 34 Iniguez MA, Pablos JL, Carreira PE, Cabre F, Gomez-Reino JJ: Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. Br J Rheumatol 1998, 37:773-778.
35. 35 Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P: Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 1998, 41:122-129.
36. 2 production.
37. 37 Towle CA, Hung HH, Bonassar LJ, Treadwell BV, Mangham DC: Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/paracrine role in pathogenesis. Osteoarthritis Cartilage 1997, 5:293-300.
38. 38 Attur MG, Patel IR, Patel RN, Abramson SB, Amin AR: Autocrine production of IL-1β by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, Prostaglandin E2 and IL-8. Proc Assoc Am Physicians 1998, 110:1-8.
39. 2 production by nitric oxide in activated murine macrophages. J Immunol 1999, in press.
40. 40 Amin AR, Vyas P, Attur MG, Leszczynska-Piziak J, Patel IR, Weissman G, Abramson SB: The mode of action of aspirin-like drugs: effect on inducibles nitric oxide synthase. Proc Natl Acad Sci U S A 1995, 92:7926-7930.
41. 41 Attur MG, Patel RN, Di Cesare P, Steiner G, Abramson SB, Amin AR: Regulation of nitric oxide production by salicylates and tenidap in human OA-affected cartilage, rat chondrosarcomas and bovine chondrocytes. Osteoarthritis Cartilage 1998, 6:269-277.
42. 2 production by CSAIDS (SB203508) in murine macrophages and bovine chondrocytes stimulated with IPS. Inflamm Res 1999, in press.
43. 43 Badger AM, Cook MN, Lark MW, Newman-Tarr TM, Swift BA, Nelson AH, et al: SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998, 161:467-473.
44. 44 Amin AR, Attur MG, Thakker GD, Patel PD, Vyas P, Patel RN, et al: A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996, 93:14014-14019.
45. 45 Rjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J: Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998, 95:15769-15774.
46. 2 is described.
47. 47 Yocum D: Cyclosporine and other experimental immunomodulatory agents. American College for Rheumatology Clinical Symposia Special Lectures Medical Aspects Lectures, 1997.
48. 2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthritis Rheum 1998, 41:2205-2210.
49. 49 Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998, 41:1591-1602.
50. 50 Clancy RM, Amin AR, Abramson SB: The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998, 41:1141-1151.
51. 2 on costochondral chondrocyte differentiation is mediated by cyclic adenosine 3′,5′-monophosphate and protein kinase C. Endocrinology 1998, 139:1825-1834.
52. 2. Exp Cell Res 1995, 218:319-325.
53. 53 Lowe GN, Fu YH, McDougall S, Polendo R, Williams A, Benya PD, Hahn TJ: Effects of prostaglandins on deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1 C5.18 chondrocyte cell line: role of second messengers. Endocrinology 1996, 137:2208-2216.
54. 54 Mohamed-Ali H: Influence of interleukin-1 beta, tumour necrosis factor alpha and prostaglandin E2 on chondrogenesis and cartilage matrix breakdown in vitro. Rheumatol Int 1995, 14:191-199.
55. 2 stimulates incorporation of proline into collagenase digestible proteins in human articular chondrocytes: identification of an effector autocrine loop involving insulin-like growth factor I. Mol Cell Endocrinol 1996, 123:27-35.
56. 56 Fukuda K, Ohtani K, Dan H, Tanaka S: Interleukin-1 inhibits keratan sulfate production by rabbit chondrocytes: possible role of prostaglandin E2. Inflamm Res 1995, 44:178-181.
57. 57 Yamada H, Kikuchi T, Nemoto O, Obata K, Sato H, Seiki M, Shiraishi A: Effects of indomethacin on the production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by human articular chondrocytes. J Rheumatol 1996, 23:1739-1743.
58. 58 Amin AR, Patel RN, Thakker GD, Lowenstein CJ, Attur MG, Abramson SB: Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycyclines and chemically modified tetracyclines. FEBS Lett 1997, 410:259-264.